StemCell Therapy

Advertisement

The company is trading unchanged by 0.00 percent from yesterdays close. Company shares last traded at $28.80 which is significantly higher than the 50 day moving average which is $25.48 and a great deal higher than the 200 day moving average of $21.36. The 50 day moving average was up $3.32 and the 200 day average went up by +34.86%.

Myriad Genetics, Inc. (Myriad), launched on November 6, 1992, is a molecular diagnostic company. The Company is involved in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individuals risk for developing disease later in life, identify a patients likelihood of responding to drug therapy and guide a patients dosing to enable optimal treatment, or assess a patients risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology..

Here are a few additional firms who have increased or decreased their stake in (MYGN). Bb&t Investment Services, Inc. trimmed its investment by shedding 31 shares a decrease of 1.0% as of 12/31/2016. Bb&t Investment Services, Inc. owns 2,927 shares valued at $49,000. The value of the position overall is down by 14.0%. As of quarter end Advisory Services Network, LLC had disposed of 200 shares trimming its holdings by 11.8%. The value of the companys investment in Myriad Genetics, Inc. increased from $32,000 to $39,000 a change of $7,000 quarter over quarter.

As of the end of the quarter Disciplined Growth Investors Inc /mn had bought a total of 2,335 shares growing its position 0.2%. The value in dollars went from $26,097,000 to $35,182,000 a change of 34.8% since the last quarter. Sterling Capital Management LLC downsized its ownership by selling 32,878 shares a decrease of 1.7%. Sterling Capital Management LLC controls 1,848,772 shares worth $47,772,000. The total value of its holdings increased 32.2%.

On August 18 the company was upgraded from Buy to Hold in a statement from Deutsche Bank. On August 9 Barclays kept the company rating at Equal-Weight but raised the price target from $22.00 to $26.00.

Myriad Genetics, Inc. currently has a P/E ratio of 90.28 and market capitalization is 1.97B. In the last earnings report the EPS was $0.32 and is estimated to be $1.02 for the current year with 68,437,000 shares presently outstanding. Analysts expect next quarters EPS to be $0.25 with next years EPS anticipated to be $1.16.

See original here:
Myriad Genetics, Inc. (MYGN) Hits a New 52-Week High - Modern Readers

This entry was posted on August 21, 2017 at 12:44 pm and is filed under Molecular Genetics. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |